A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle

Bone Marrow Transplantation

Volumn 25, Issue 5, 2000, Pages 519-524

  Bashey, A ^a   Corringham, S ^a   Garrett, J ^a   Lane, T A ^a   Gilpin, E A ^a   Corringham, R E T ^a   Law, L ^a   Ho, A D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Breast cancer; High dose chemotherapy; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; TAMOXIFEN; THIOTEPA;

ADULT; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOXICITY; FEMALE; HEALTH INSURANCE; HEMATURIA; HUMAN; HUMAN CELL; HYPERTENSION; HYPONATREMIA; HYPOTENSION; INFECTION; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPTICEMIA; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0034012053     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702172     Document Type: Article

References (26)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Clark G, Sledge GW, Osborne CK et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1987; 5: 55-61.
3. Mick R, Begg CB, Antman K et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989; 13: 33-38.
4. Peters WP, Shpall EJ, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
5. Vincent MD, Powles TJ, Coombes RC, McElwain TJ. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol 1988; 21: 255-260.
6. Williams SF, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
7. Dunphy FR, Spitzer G, Buzdar AU et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
8. Kennedy MJ, Beveridge RA, Rowley SD et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
9. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743-1747.
10. Antman KH, Rowlings PA, Vaughan WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
11. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial (see comments). J Clin Oncol 1995; 13: 2483-2489.
12. Rizzieri DA, Vredenburgh JJ, Chao NJ et al. Long-term disease-free survival for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose therapy with hematopoietic support. Blood 1998; 92: 323a.
13. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70: 163-169.
14. Philip T, Ladenstein R, Zucker JM et al. Double megatherapy and autologous bone marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 1993; 67: 119-127.
15. Ayash LJ, Elias A, Wheeler C et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994; 12: 37-44.
16. Bitran JD, Samuels B, Klein L et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157-162.
17. McClay EF, Albright KD, Jones JA et al. Tamoxifen modulation of cisplatin cytotoxicily in human malignancies. Int J Cancer 1993; 55: 1018-1022.
18. McClay EF, Albright KD, Jones JA et al. Tamoxiten delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 1994; 70: 449-452.
19. McClay EF, McClay ME, Jones JA et al. A phase I and pharmucokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. Cancer 1997; 79: 1037-1043.
20. Crown J, Norton L. Potential strategies for improving the results of high-dose chemotherapy in patients with metastatic breast cancer. Ann Oncol 1995; 6: 21-26.
21. Ayash LJ, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-2992.
22. Ghalie R, Williams S, Valentino LA et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995; 1: 40-46.
23. Honkoop AH, van der Wall E, Feller N et al. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer (see comments). Ann Oncol 1997; 8: 957-962.
24. Viens P, Gravis G, Genre D et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrow Transplant 1997; 20: 199-203.
25. Danova M, Perotti C, Mora O et al. Multicyclic dose-intensive chemotherapy with circulating progenitor cell support for high-risk primary breast cancer. Oncol Rep 1998; 5: 427-429.
26. Hohaus S, Wallwiener D, Martin S et al. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Semin Oncol 1998; 25 (Suppl. 4): 7-11; Discussion 45-48.